HELIX NEWS!! - 500 Beiträge pro Seite

[Feussi]

Thursday August 17, 10:08 am Eastern Time
Press Release
Helix BioPharma Corp.: Core European Patent Granted For Drug Delivery Technology
AURORA, Ontario--(BW HealthWire)--Aug. 17, 2000--Helix BioPharma Corp. (TSE:HBP. - news; Frankfurt:HBP)

A core patent respecting Helix`s injectionless BIPHASIX(TM) drug and vaccine delivery technology has been granted by the European Patent Office.

This new patent adds to Helix`s growing portfolio of intellectual property, which includes patents for Helix`s drug and vaccine delivery systems, biosensor technology and anti-infective therapeutics.

``The foundation for the protection of our unique drug delivery system has now been extended across the European Union,`` stated Helix Chairman, Jerry McElroy. ``Coupled with existing U.S. patents both issued and pending, Helix`s drug delivery system is gaining significant patent protection which will aid in commercializing the technology through a number of products, such as the insulin patch and interferon-alpha cream currently in development.``

Helix is developing an insulin patch using the BIPHASIX(TM) delivery system to deliver a steady basal level of insulin for the treatment of diabetes. In addition, the Company is developing an interferon-alpha cream for the treatment of human papilloma virus (``HPV``) infections and early stage cervical cancer.

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. Information contained in this news release may include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially.

Helix BioPharma trades on the TSE and FSE under the symbol ``HBP``.

[seminole]

Ende September 2000 wird es ein meeting für Investoren geben.